Bio-production CMO & CRO Market

Market Definition

The Bio-production CMO & CRO Market size was valued at USD 35.3 billion in 2023 and is predicted to reach USD 52.1 billion by 2030 with a CAGR of 5.7% from 2024-2030.

Bio-production CMO (Contract Manufacturing Organization) and CRO (Contract Research Organization) are two entities in the biotechnology and pharmaceutical industries. A bio-production CMO specializes in manufacturing biological products on a contract basis for other companies. They have the necessary infrastructure and expertise to produce complex biopharmaceuticals such as therapeutic proteins, vaccines, and cell therapies. By outsourcing manufacturing to CMOs, companies can focus on their core competencies while benefiting from the CMO's manufacturing capabilities.

On the other hand, a bio-production CRO offers contract research services for the development and optimization of bioprocesses. They assist in various aspects of bioprocess development, including cell line development, fermentation optimization, and analytical method development. CROs provide technical expertise and facilities to help companies accelerate the development of their biologics manufacturing processes. Both CMOs and CROs play vital roles in supporting the biopharmaceutical industry by facilitating efficient and cost-effective production of biological products.

Market Dynamics and Trends

The increasing number of clinical trials in personalized medicine and targeted therapies is driving the demand for bio-production CMO and CRO services, facilitating the development and commercialization of tailored treatments. According to a recent report published by the World Health Organization, around 48,000 clinical trials are ongoing worldwide in 2022. With such a substantial number of trials underway, there is a growing need for contract manufacturing and research organizations to support the production and testing of these innovative therapies, thus driving the growth of the market.

Moreover, the increasing demand for biologics, including therapeutic proteins, antibodies, and cell therapies, is driving the need for bio-production CMO and CRO services. Biologics offer significant advantages in treating various diseases, leading to a surge in research and development activities aimed at developing novel biologic therapies. 

As a result, pharmaceutical and biotechnology companies are increasingly relying on contract manufacturing and research organizations to support the production, development, and testing of these biologic drugs, thereby boosting the growth of the market.

However, the high costs associated with equipment, facilities, and regulatory compliance along with the complex nature of manufacturing biologics and conducting clinical trials are the major factors restraining the growth of the market.

On the contrary, the introduction of advanced technologies such as artificial intelligence and machine learning algorithms is expected to create ample opportunities for market growth in the coming years. These technologies enable more efficient data analysis, predictive modeling, and automation of processes, leading to enhanced productivity, cost savings, and improved decision-making capabilities for businesses operating in various industries.

Market Segmentations and Scope of the Study

The bio-production CMO & CRO market share is segmented on the basis of products, services, application, and region. On the basis of products, the market is divided into biologics, antisense, RNAi, & molecular therapy and bio-similar. On the basis of services, the market is classified into contract manufacturing and contract research. On the basis of application, the market is classified into oncology, inflammation & immunology, cardiology, and neuroscience. Regional breakdown and analysis of each of the aforesaid segments include regions comprising of North America, Europe, Asia-Pacific, and Rest of the World (RoW).

Geographical Analysis

North America holds the dominant share of bio-production CMO & CRO market and is expected to continue its dominance during the forecast period. This is attributed to factors such as the growing investment in clinical trials by both government and pharmaceutical companies in this region. As per the recent report from World Health Organization, the U.S. conducts the largest number of clinical trials across the globe, with 9900 clinicals trials per year.

Moreover, the presence of key market players such as plays an important role in the growth of the market in this region. For instance, in March 2024, Tonix Pharmaceuticals partnered with two Contract Manufacturing Organizations, one of which is Almac Pharma Services. The partnership aims to support the commercial launch and ongoing supply of a new non-opioid analgesic to patients with fibromyalgia, a chronic debilitating disease.

On the other hand, Asia-Pacific is expected to show a steady growth in the bio-production CMO & CRO market. This is due to the presence of one of the largest pharmaceutical industries in this region. As per the latest report published by the Department of Pharmaceuticals of India, India is a major exporter of pharmaceuticals, serving over 200 countries with its exports. Also, the pharmaceutical industry in India is expected to reach USD 65 billion by 2024 and USD 130 billion by 2030, creating lucrative opportunities for the growth of the market in this region.

Moreover, surge in investments in research and development of drugs in the country by various multinational companies further propels the growth of the market. According to the Korea Research-based Pharma Industry Association (KRPIA), various multinational drug companies have expanded their R&D investment in South Korea by 20%, with year-on-year investment growing to USD 499.5 million in 2021-22.

Competitive Landscape

Various market players operating in the bio-production CMO & CRO market include Cerba Healthcare, BioEclipse Therapeutics, Lonza, Boehringer Ingelheim, FUJIFILM Diosynth Biotechnologies U.S.A., Samsung BioLogics, AbbVie Inc., Almac Pharma Services, Inno Biologics Sdn Bhd, Toyobo Co. Ltd., and others. These market players are adopting various strategies such as acquisition and invitation to remain dominate in the market.

For instance, in October 2023, Lonza collaborated with Vaxcyte a new commercial manufacturing agreement. The collaboration was aimed to expand Global Commercial Manufacturing of Broad-Spectrum Pneumococcal Conjugate Vaccines (PCVs).

Moreover, in February 2021, BioEclipse announced to invite pitches from CROs and CMOs for the Phase II of their advanced solid tumor basket trial. The move aims to advance their research and development efforts in the field of oncology and bring innovative treatments for patients with solid tumors.

Key Benefits

• The report provides quantitative analysis and estimations of the bio-production CMO & CRO market from 2024 to 2030, which assists in identifying the prevailing market opportunities.

• The study comprises a deep-dive analysis of the bio-production CMO & CRO market including the current and future trends to depict prevalent investment pockets in the market.

• Information related to key drivers, restraints, and opportunities and their impact on the bio-production CMO & CRO market is provided in the report.

• Competitive analysis of the players, along with their market share is provided in the report.

• SWOT analysis and Porters Five Forces model is elaborated in the study.

• Value chain analysis in the market study provides a clear picture of roles of stakeholders.

Key Market Segments

By Products 

• Biologics

• Antisense

• RNAi & Molecular Therapy

• Bio-Similar

By Services 

• Contract Manufacturing

• Contract Research

By Application 

• Oncology

• Inflammation & Immunology

• Cardiology

• Neuroscience

By Region

• North America

  • The U.S.

  • Canada

  • Mexico

• Europe

  • The U.K.

  • Germany

  • France        

  • Italy        

  • Spain        

  • Denmark        

  • Netherlands        

  • Finland        

  • Sweden        

  • Norway        

  • Russia        

  • Rest of Europe

• Asia-Pacific

  • China

  • Japan

  • India

  • South Korea

  • Australia

  • Indonesia

  • Singapore

  • Taiwan

  • Thailand

  • Rest of Asia-Pacific 

• Rest of the World (RoW)

  • Latin America

  • Middle East 

  • Africa

REPORT SCOPE AND SEGMENTATION:

Parameters	Details
Market Size in 2023	USD 35.3 billion
Revenue Forecast in 2030	USD 52.1 billion
Growth Rate	CAGR of 5.7% 2024 to 2030
Analysis Period	2023–2030
Base Year Considered	2023
Forecast Period	2024–2030
Market Size Estimation	Billion (USD)
Growth Factors	Increasing number of clinical trials across the globe Rising demand for advanced medication and biologics
Countries Covered	28
Companies Profiled	10
Market Share	Available for 10 companies
Customization Scope	Free customization (equivalent to up to 80 working hours of analysts) after purchase. Addition or alteration to country, regional, and segment scope.
Pricing and Purchase Options	Avail customized purchase options to meet your exact research needs.

KEY PLAYERS

• Cerba Healthcare

• BioEclipse Therapeutics

• Lonza

• Boehringer Ingelheim

• FUJIFILM Diosynth Biotechnologies U.S.A

• Samsung BioLogics

• AbbVie Inc.

• Almac Pharma Services 

• Inno Biologics Sdn Bhd

• Toyobo Co. Ltd.